Endocrine treatment options for advanced breast cancer – the role of fulvestrant

J.F.R. Robertson; Steven E. Come; Stephen E. Jones; L.V.A.M. Beex; M. Kaufmann; Andreas Makris; J.W.R. Nortier; K. Possinger; L. E. Rutqvist

doi:10.1016/j.ejca.2004.07.035

Keywords

FulvestrantAnastrozoleTamoxifenExemestaneMedicineBreast cancerLetrozoleOncologyInternal medicineSelective estrogen receptor modulatorAntiestrogenRaloxifeneToremifeneAromatase inhibitorCancerAromatasePharmacology

Affiliated Institutions

Related Publications

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner , Dennis J. Slamon , Jungsil Ro +16 more

Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant res...

2018 New England Journal of Medicine 1180 citations

The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors

Brian W. Walsh

A bstract : Raloxifene, a selective estrogen receptor modulator, favorably alters several markers of cardiovascular risk in healthy postmenopausal women. While many of its effec...

2001 Annals of the New York Academy of Sci... 17 citations

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André , Eva Ciruelos , Gábor Rubovszky +17 more

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had rec...

2019 New England Journal of Medicine 2305 citations

Estrogenic Regulation of Growth and Polypeptide Growth Factor Secretion in Human Breast Carcinoma

Robert B. Dickson , Marc E. Lippman

HORMONAL influences on cancer cell proliferation have recently received much attention with the proposal of autocrine or self-stimulating polypeptide growth factors (1). The gro...

1987 Endocrine Reviews 576 citations

Tamoxifen for early breast cancer: Better late than never

Richard Gray , Christina Davies , Paul Perry

2000 Annals of Oncology 5 citations

Publication Info

Year: 2004
Type: review
Volume: 41
Issue: 3
Pages: 346-356
Citations: 78
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Endocrine treatment options for advanced breast cancer – the role of fulvestrant

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    J.F.R. Robertson, 
                                
                                    Steven E. Come, 
                                
                                    Stephen E. Jones
                                
                                et al.
                            
                            (2004). 
                            Endocrine treatment options for advanced breast cancer – the role of fulvestrant. 
                            European Journal of Cancer
                            , 41
                            (3)
                            , 346-356.
                            https://doi.org/10.1016/j.ejca.2004.07.035
                        

Identifiers

DOI: 10.1016/j.ejca.2004.07.035